REGENDO is a biotech startup that has developed the world’s first implantable, tissue-engineered thyroid scaffold created from a patient’s own fat cells. Its proprietary hydrogel delivery system offers a long-term, single-application functional cure for hypothyroidism, overcoming the limitations of existing treatments by restoring natural thyroid function.
REGENDO
![](https://researchpark.illinois.edu/wp-content/uploads/2024/12/Screenshot-2024-10-01-173812-600x600-1-150x150.png)